Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

[Image: see text] The imidazolyl-tetrahydro-β-carboline class of sstr3 antagonists have demonstrated efficacy in a murine model of glucose excursion and may have potential as a treatment for type 2 diabetes. The first candidate in this class caused unacceptable QTc interval prolongation in oral, tel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ACS Med Chem Lett
Egile Nagusiak: Shah, Shrenik K., He, Shuwen, Guo, Liangqin, Truong, Quang, Qi, Hongbo, Du, Wu, Lai, Zhong, Liu, Jian, Jian, Tianying, Hong, Qingmei, Dobbelaar, Peter, Ye, Zhixiong, Sherer, Edward, Feng, Zhe, Yu, Yang, Wong, Frederick, Samuel, Koppara, Madiera, Maria, Karanam, Bindhu V., Reddy, Vijay B., Mitelman, Stan, Tong, Sharon X., Chicchi, Gary G., Tsao, Kwei-Lan, Trusca, Dorina, Feng, Yue, Wu, Margaret, Shao, Qing, Trujillo, Maria E., Eiermann, George J., Li, Cai, Pachanski, Michele, Fernandez, Guillermo, Nelson, Donald, Bunting, Patricia, Morissette, Pierre, Volksdorf, Sylvia, Kerr, Janet, Zhang, Bei B., Howard, Andrew D., Zhou, Yun-Ping, Pasternak, Alexander, Nargund, Ravi P., Hagmann, William K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Chemical Society 2015
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434471/
https://ncbi.nlm.nih.gov/pubmed/26005524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml500514w
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak